Lilly psoriasis drug fares well in late-stage test

August 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

The Indianapolis-based company announced initial results from the research on Thursday and said it plans to submit the drug, ixekizumab, to regulators in the first half of next year. The drugmaker has been pushing to develop new treatments to replace revenue lost due to a wave of patent expirations that have hit top-selling drugs like the antidepressant Cymbalta.

In the ixekizumab research, between 31% and 41% of the patients taking its drug achieved clear skin, according to the drugmaker. Overall, those on the drug achieved better levels of skin clearance than patients taking a fake treatment or etanercept, which goes by the brand name Enbrel and is sold by Amgen Inc. and Pfizer Inc.

Psoriasis is a chronic disease that occurs when a person's immune system speeds up the growth cycle of skin cells. The most common form, plaque psoriasis, creates raised, red patches on the skin.

Explore further: Eli Lilly 2013 profit forecast tops expectations

Related Stories

Eli Lilly 2013 profit forecast tops expectations

January 4, 2013

(AP)—Eli Lilly and Co. said Friday its 2013 earnings will grow more than Wall Street expects, even though the drugmaker will lose U.S. patent protection for two more key products this year.

Skin care tips for psoriasis patients

August 25, 2013

(HealthDay)—Sun protection is among the skin care habits that can help people with the chronic skin condition psoriasis reduce some of the discomfort they may experience, such as skin itching, cracking and bleeding, an ...

New target for psoriasis treatment discovered

February 12, 2014

Researchers at King's College London have identified a new gene (PIM1), which could be an effective target for innovative treatments and therapies for the human autoimmune disease, psoriasis.

AstraZeneca says DOJ closes probe into drug trial

August 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.